Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1776

1.

Somnolence Preceded the Development of a Subthalamic Lesion in Neuromyelitis Optica Spectrum Disorder: A Case Report.

Daida K, Ogaki K, Hayashida A, Ando M, Yokoyama K, Noda K, Kanbayashi T, Hattori N, Okuma Y.

Intern Med. 2019 Oct 15. doi: 10.2169/internalmedicine.2947-19. [Epub ahead of print]

2.

Modified Systemic Inflammation Score is Useful for Risk Stratification After Radical Resection of Squamous Cell Carcinoma of the Esophagus.

Kanda M, Koike M, Tanaka C, Kobayashi D, Hattori N, Hayashi M, Yamada S, Omae K, Fujiwara M, Kodera Y.

Ann Surg Oncol. 2019 Oct 11. doi: 10.1245/s10434-019-07914-7. [Epub ahead of print]

PMID:
31605344
3.

Mutations in CHCHD2 cause α-synuclein aggregation.

Ikeda A, Nishioka K, Meng H, Takanashi M, Inoshita T, Shiba-Fukushima K, Li Y, Yoshino H, Mori A, Okuzumi A, Yamaguchi A, Nonaka R, Izawa N, Ishikawa KI, Saiki H, Morita M, Hasegawa M, Hasegawa K, Elahi M, Funayama M, Okano H, Akamatsu W, Imai Y, Hattori N.

Hum Mol Genet. 2019 Oct 10. pii: ddz241. doi: 10.1093/hmg/ddz241. [Epub ahead of print]

PMID:
31600778
4.

Mutation analysis of LRP10 in Japanese patients with familial Parkinson's disease, progressive supranuclear palsy, and frontotemporal dementia.

Daida K, Nishioka K, Li Y, Yoshino H, Kikuchi A, Hasegawa T, Funayama M, Hattori N.

Neurobiol Aging. 2019 Sep 6. pii: S0197-4580(19)30309-4. doi: 10.1016/j.neurobiolaging.2019.08.030. [Epub ahead of print]

PMID:
31582232
5.

Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.

Nakao S, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N.

Anticancer Res. 2019 Oct;39(10):5725-5731. doi: 10.21873/anticanres.13773.

PMID:
31570474
6.

Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy.

Mori A, Ishikawa KI, Saiki S, Hatano T, Oji Y, Okuzumi A, Fujimaki M, Koinuma T, Ueno SI, Imamichi Y, Hattori N.

PLoS One. 2019 Sep 27;14(9):e0223113. doi: 10.1371/journal.pone.0223113. eCollection 2019.

7.

Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways.

Moro H, Hattori N, Nakamura Y, Kimura K, Imai T, Maeda M, Yashiro M, Ushijima T.

Gastric Cancer. 2019 Sep 25. doi: 10.1007/s10120-019-01010-1. [Epub ahead of print]

PMID:
31555951
8.

Parkinson's disease-associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling.

Mori A, Hatano T, Inoshita T, Shiba-Fukushima K, Koinuma T, Meng H, Kubo SI, Spratt S, Cui C, Yamashita C, Miki Y, Yamamoto K, Hirabayashi T, Murakami M, Takahashi Y, Shindou H, Nonaka T, Hasegawa M, Okuzumi A, Imai Y, Hattori N.

Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20689-20699. doi: 10.1073/pnas.1902958116. Epub 2019 Sep 23.

9.

Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II).

Hattori N, Nakayama G, Uehara K, Aiba T, Ishigure K, Sakamoto E, Tojima Y, Kanda M, Kobayashi D, Tanaka C, Yamada S, Koike M, Fujiwara M, Nagino M, Kodera Y.

Int J Clin Oncol. 2019 Sep 21. doi: 10.1007/s10147-019-01546-3. [Epub ahead of print]

PMID:
31542847
10.

Metabolomic analysis revealed mitochondrial dysfunction and aberrant choline metabolism in MPP+-exposed SH-SY5Y cells.

Amo T, Oji Y, Saiki S, Hattori N.

Biochem Biophys Res Commun. 2019 Nov 12;519(3):540-546. doi: 10.1016/j.bbrc.2019.09.031. Epub 2019 Sep 16.

PMID:
31537380
11.

MR g-ratio-weighted connectome analysis in patients with multiple sclerosis.

Kamagata K, Zalesky A, Yokoyama K, Andica C, Hagiwara A, Shimoji K, Kumamaru KK, Takemura MY, Hoshino Y, Kamiya K, Hori M, Pantelis C, Hattori N, Aoki S.

Sci Rep. 2019 Sep 18;9(1):13522. doi: 10.1038/s41598-019-50025-2.

12.

Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer.

Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Mimae T, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N.

Int J Clin Oncol. 2019 Sep 17. doi: 10.1007/s10147-019-01539-2. [Epub ahead of print]

PMID:
31531785
13.

Skeletal muscle function and need for long-term care of urban elderly people in Japan (the Bunkyo Health Study): a prospective cohort study.

Someya Y, Tamura Y, Kaga H, Nojiri S, Shimada K, Daida H, Ishijima M, Kaneko K, Aoki S, Miida T, Hirayama S, Konishi S, Hattori N, Motoi Y, Naito H, Kawamori R, Watada H.

BMJ Open. 2019 Sep 17;9(9):e031584. doi: 10.1136/bmjopen-2019-031584.

14.

Procedures for the diagnosis of macro-follicle stimulating hormone (FSH) in a patient with high serum FSH concentrations.

Chihara K, Hattori N, Matsuda T, Murasawa S, Daimon M, Shimatsu A.

Clin Chem Lab Med. 2019 Sep 17. pii: /j/cclm.ahead-of-print/cclm-2019-0846/cclm-2019-0846.xml. doi: 10.1515/cclm-2019-0846. [Epub ahead of print] No abstract available.

PMID:
31525153
15.

White Matter Abnormalities in Multiple Sclerosis Evaluated by Quantitative Synthetic MRI, Diffusion Tensor Imaging, and Neurite Orientation Dispersion and Density Imaging.

Hagiwara A, Kamagata K, Shimoji K, Yokoyama K, Andica C, Hori M, Fujita S, Maekawa T, Irie R, Akashi T, Wada A, Suzuki M, Abe O, Hattori N, Aoki S.

AJNR Am J Neuroradiol. 2019 Oct;40(10):1642-1648. doi: 10.3174/ajnr.A6209. Epub 2019 Sep 12.

PMID:
31515218
16.

A Case of New-onset Refractory Status Epilepticus Involving the Limbic System, Spinal Cord, and Peripheral Nerves.

Daida K, Nishioka K, Takanashi M, Kobayashi M, Yoshikawa K, Kusunoki S, Yokoyama K, Hattori N.

Intern Med. 2019 Sep 11. doi: 10.2169/internalmedicine.3510-19. [Epub ahead of print]

17.

Temporal Features of Muscle Synergies in Sit-to-stand Motion Reflect the Motor Impairment of Post-Stroke Patients.

Yang N, An Q, Kogami H, Yamakawa H, Tamura Y, Takahashi K, Kinomoto M, Yamasaki H, Itkonen M, Sshibata-Alnajjar F, Shimoda S, Hattori N, Fujii T, Otomune H, Miyai I, Yamashita A, Asama H.

IEEE Trans Neural Syst Rehabil Eng. 2019 Sep 4. doi: 10.1109/TNSRE.2019.2939193. [Epub ahead of print]

PMID:
31494552
18.

Pulmonary cryptococcosis mimicking lung cancer.

Taniwaki M, Yamasaki M, Ishikawa N, Kawamoto K, Hattori N.

Lancet Infect Dis. 2019 Sep;19(9):1033. doi: 10.1016/S1473-3099(19)30278-6. No abstract available.

PMID:
31478508
19.

Balance and Gait Improvements of Postoperative Rehabilitation in Patients with Parkinson's Disease Treated with Subthalamic Nucleus Deep Brain Stimulation (STN-DBS).

Sato K, Aita N, Hokari Y, Kitahara E, Tani M, Izawa N, Hatori K, Nakamura R, Sasaki F, Sekimoto S, Jo T, Oyama G, Hatano T, Shimo Y, Iwamuro H, Umemura A, Hattori N, Fujiwara T.

Parkinsons Dis. 2019 Aug 4;2019:7104071. doi: 10.1155/2019/7104071. eCollection 2019.

20.

Serum Antibody against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer.

Ohue Y, Kurose K, Karasaki T, Isobe M, Yamaoka T, Futami J, Irei I, Masuda T, Fukuda M, Kinoshita A, Matsushita H, Shimizu K, Nakata M, Hattori N, Yamaguchi H, Fukuda M, Nozawa R, Kakimi K, Oka M.

J Thorac Oncol. 2019 Aug 23. pii: S1556-0864(19)30691-4. doi: 10.1016/j.jtho.2019.08.008. [Epub ahead of print]

21.

Clinical Characterization of Definite Autoimmune Limbic Encephalitis: A 30-case Series.

Shojima Y, Nishioka K, Watanabe M, Jo T, Tanaka K, Takashima H, Noda K, Okuma Y, Urabe T, Yokoyama K, Hattori N.

Intern Med. 2019 Aug 21. doi: 10.2169/internalmedicine.3029-19. [Epub ahead of print]

22.

Neuroprotective effects of memantine via enhancement of autophagy.

Hirano K, Fujimaki M, Sasazawa Y, Yamaguchi A, Ishikawa KI, Miyamoto K, Souma S, Furuya N, Imamichi Y, Yamada D, Saya H, Akamatsu W, Saiki S, Hattori N.

Biochem Biophys Res Commun. 2019 Oct 8;518(1):161-170. doi: 10.1016/j.bbrc.2019.08.025. Epub 2019 Aug 17.

PMID:
31431260
23.

Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy.

Yoshiya T, Mimae T, Ito M, Sasada S, Tsutani Y, Satoh K, Masuda T, Miyata Y, Hattori N, Okada M.

Invest New Drugs. 2019 Aug 19. doi: 10.1007/s10637-019-00836-x. [Epub ahead of print]

PMID:
31428894
24.

C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis.

Watanabe M, Horimasu Y, Iwamoto H, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Ohshimo S, Fujitaka K, Hamada H, Kohno N, Hattori N.

Respiration. 2019;98(3):212-220. doi: 10.1159/000500576. Epub 2019 Aug 15.

25.

Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report.

Yamasaki M, Funaishi K, Kawamoto K, Matsumoto Y, Matsumoto N, Taniwaki M, Ohashi N, Hattori N.

Medicine (Baltimore). 2019 Aug;98(33):e16834. doi: 10.1097/MD.0000000000016834.

26.

[EVALUATION OF A MOTOR AND SENSORY DISTURBANCE QUESTIONNAIRE FOR PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS].

Ueki Y, Oshikata C, Asai Y, Kaneko T, Hattori N, Tsurikisawa N.

Arerugi. 2019;68(7):857-868. doi: 10.15036/arerugi.68.857. Japanese.

PMID:
31406082
27.

Convolutional neural network-based segmentation can help in assessing the substantia nigra in neuromelanin MRI.

Le Berre A, Kamagata K, Otsuka Y, Andica C, Hatano T, Saccenti L, Ogawa T, Takeshige-Amano H, Wada A, Suzuki M, Hagiwara A, Irie R, Hori M, Oyama G, Shimo Y, Umemura A, Hattori N, Aoki S.

Neuroradiology. 2019 Aug 10. doi: 10.1007/s00234-019-02279-w. [Epub ahead of print]

PMID:
31401723
28.

Pilot feasibility study of a semi-automated three-dimensional scoring system for cervical dystonia.

Nakamura T, Sekimoto S, Oyama G, Shimo Y, Hattori N, Kajimoto H.

PLoS One. 2019 Aug 8;14(8):e0219758. doi: 10.1371/journal.pone.0219758. eCollection 2019.

29.

Free-Water Imaging in White and Gray Matter in Parkinson's Disease.

Andica C, Kamagata K, Hatano T, Saito A, Uchida W, Ogawa T, Takeshige-Amano H, Zalesky A, Wada A, Suzuki M, Hagiwara A, Irie R, Hori M, Kumamaru KK, Oyama G, Shimo Y, Umemura A, Pantelis C, Hattori N, Aoki S.

Cells. 2019 Aug 5;8(8). pii: E839. doi: 10.3390/cells8080839.

30.

Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.

Kamo H, Hatano T, Kanai K, Aoki N, Kamiyama D, Yokoyama K, Takanashi M, Yamashita Y, Shimo Y, Hattori N.

BMC Neurol. 2019 Aug 5;19(1):184. doi: 10.1186/s12883-019-1416-1.

31.

Novel prodrugs of decitabine with greater metabolic stability and less toxicity.

Hattori N, Sako M, Kimura K, Iida N, Takeshima H, Nakata Y, Kono Y, Ushijima T.

Clin Epigenetics. 2019 Aug 1;11(1):111. doi: 10.1186/s13148-019-0709-y.

32.

[Indication for Deep Brain Stimulation].

Shimo Y, Umemura A, Hattori N.

Brain Nerve. 2019 Aug;71(8):885-892. doi: 10.11477/mf.1416201369. Review. Japanese.

PMID:
31346145
33.

Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis.

Kuwahara K, Ohba S, Nakae S, Hattori N, Pareira ES, Yamada S, Sasaki H, Abe M, Hasegawa M, Hirose Y.

Brain Tumor Pathol. 2019 Oct;36(4):135-143. doi: 10.1007/s10014-019-00348-9. Epub 2019 Jul 19.

PMID:
31324999
34.

Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone.

Lee JS, Kanai K, Suzuki M, Kim WS, Yoo HS, Fu Y, Kim DK, Jung BC, Choi M, Oh KW, Li Y, Nakatani M, Nakazato T, Sekimoto S, Funayama M, Yoshino H, Kubo SI, Nishioka K, Sakai R, Ueyama M, Mochizuki H, Lee HJ, Sardi SP, Halliday GM, Nagai Y, Lee PH, Hattori N, Lee SJ.

Brain. 2019 Sep 1;142(9):2845-2859. doi: 10.1093/brain/awz205.

PMID:
31312839
35.

Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis.

Nishida Y, Takahashi YK, Kanai T, Nose Y, Ishibashi S, Sanjo N, Uzawa A, Oda F, Ozawa Y, Kuwabara S, Noguchi E, Suzuki S, Nakahara J, Suzuki N, Ogawa T, Yokoyama K, Hattori N, Konno S, Fujioka T, Kawaguchi N, Hatanaka Y, Sonoo M, Kaneko J, Ogino M, Nishiyama K, Nomura K, Yokota T.

Eur J Neurol. 2019 Jul 15. doi: 10.1111/ene.14039. [Epub ahead of print]

PMID:
31309642
36.

Protective Role of Levetiracetam Against Cognitive Impairment And Brain White Matter Damage in Mouse prolonged Cerebral Hypoperfusion.

Inaba T, Miyamoto N, Hira K, Ueno Y, Yamashiro K, Watanabe M, Shimada Y, Hattori N, Urabe T.

Neuroscience. 2019 Aug 21;414:255-264. doi: 10.1016/j.neuroscience.2019.07.015. Epub 2019 Jul 11.

PMID:
31302262
37.

A Case of Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis.

Yamada T, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Hirata S, Fujitaka K, Hamada H, Sugiyama E, Hattori N.

Intern Med. 2019 Jul 10. doi: 10.2169/internalmedicine.3018-19. [Epub ahead of print]

38.

[Development of cardiac tamponade and emergence of arrhythmia during chemotherapy for diffuse large B-cell lymphoma].

Baba Y, Saito B, Shimada S, Sasaki Y, Murai S, Abe M, Fujiwara S, Arai N, Kawaguchi Y, Kabasawa N, Tsukamoto H, Uto Y, Yanagisawa K, Hattori N, Harada H, Nakamaki T.

Rinsho Ketsueki. 2019;60(6):577-581. doi: 10.11406/rinketsu.60.577. Japanese.

PMID:
31281147
39.

Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis.

Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N.

Respirology. 2019 Jul 3. doi: 10.1111/resp.13634. [Epub ahead of print]

PMID:
31270920
40.

Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.

Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N.

Respir Investig. 2019 Sep;57(5):451-459. doi: 10.1016/j.resinv.2019.05.002. Epub 2019 Jun 24.

PMID:
31248832
41.

Changes in acute blood purification therapy in critical care: republication of the article published in the Japanese Journal of Artificial Organs.

Nakada TA, Oda S, Abe R, Hattori N.

J Artif Organs. 2019 Jun 24. doi: 10.1007/s10047-019-01113-7. [Epub ahead of print] Review.

PMID:
31236729
42.

Brain tissue and myelin volumetric analysis in multiple sclerosis at 3T MRI with various in-plane resolutions using synthetic MRI.

Saccenti L, Andica C, Hagiwara A, Yokoyama K, Takemura MY, Fujita S, Maekawa T, Kamagata K, Le Berre A, Hori M, Hattori N, Aoki S.

Neuroradiology. 2019 Jun 18. doi: 10.1007/s00234-019-02241-w. [Epub ahead of print]

PMID:
31209528
43.

Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: A multicenter, single-arm study.

Iozumi K, Abe M, Ito Y, Uesugi T, Onoduka T, Kato I, Kato F, Kodama K, Takahashi H, Takeda O, Tomizawa K, Nomiyama T, Fujii M, Mayama J, Muramoto F, Yasuda H, Yamanaka K, Sato T, Oh-I T, Kasai H, Tsuboi R, Hattori N, Maruyama R, Omi T, Shimoyama H, Sei Y, Nakasu I, Nishimoto S, Hata Y, Mochizuki T, Fukuzawa M, Seishima M, Sugiura K, Katayama I, Yamamoto O, Shindo M, Kiryu H, Kusuhara M, Takenaka M, Watanabe S.

J Dermatol. 2019 Aug;46(8):641-651. doi: 10.1111/1346-8138.14935. Epub 2019 Jun 17.

44.

Pneumatosis cystoides intestinalis in pulmonary mycobacterial disease.

Yamasaki M, Teshima H, Okanobu H, Hattori N.

Br J Hosp Med (Lond). 2019 Jun 2;80(6):iii. doi: 10.12968/hmed.2019.80.6.iii. No abstract available.

PMID:
31180773
45.

Deep brain stimulation shows high efficacy in two patients with GCH1 variants.

Daida K, Nishioka K, Shimo Y, Umemura A, Yoshino H, Hattori N.

Parkinsonism Relat Disord. 2019 Aug;65:277-278. doi: 10.1016/j.parkreldis.2019.06.002. Epub 2019 Jun 3. No abstract available.

PMID:
31178337
46.

Parkinson's disease in the Western Pacific Region.

Lim SY, Tan AH, Ahmad-Annuar A, Klein C, Tan LCS, Rosales RL, Bhidayasiri R, Wu YR, Shang HF, Evans AH, Pal PK, Hattori N, Tan CT, Jeon B, Tan EK, Lang AE.

Lancet Neurol. 2019 Sep;18(9):865-879. doi: 10.1016/S1474-4422(19)30195-4. Epub 2019 Jun 4. Review.

PMID:
31175000
47.

More subjects are required for ventrolateral than dorsolateral prefrontal TMS because of intolerability and potential drop-out.

Han S, Ogawa A, Osada T, Suda A, Tanaka M, Nanjo H, Shimo Y, Hattori N, Konishi S.

PLoS One. 2019 Jun 3;14(6):e0217826. doi: 10.1371/journal.pone.0217826. eCollection 2019.

48.

A metabolic profile of polyamines in parkinson disease: A promising biomarker.

Saiki S, Sasazawa Y, Fujimaki M, Kamagata K, Kaga N, Taka H, Li Y, Souma S, Hatano T, Imamichi Y, Furuya N, Mori A, Oji Y, Ueno SI, Nojiri S, Miura Y, Ueno T, Funayama M, Aoki S, Hattori N.

Ann Neurol. 2019 Aug;86(2):251-263. doi: 10.1002/ana.25516. Epub 2019 Jul 1.

49.

Gray Matter Alterations in Early and Late Relapsing-Remitting Multiple Sclerosis Evaluated with Synthetic Quantitative Magnetic Resonance Imaging.

Andica C, Hagiwara A, Kamagata K, Yokoyama K, Shimoji K, Saito A, Takenaka Y, Nakazawa M, Hori M, Cohen-Adad J, Takemura MY, Hattori N, Aoki S.

Sci Rep. 2019 May 31;9(1):8147. doi: 10.1038/s41598-019-44615-3.

50.

Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson's disease?

Okuzumi A, Hatano T, Kamagata K, Hori M, Mori A, Oji Y, Taniguchi D, Daida K, Shimo Y, Yanagisawa N, Nojiri S, Aoki S, Hattori N.

Eur J Neurol. 2019 Nov;26(11):1408-1416. doi: 10.1111/ene.14009. Epub 2019 Jun 24.

PMID:
31136060

Supplemental Content

Loading ...
Support Center